The global lung cancer genomic testing market size was valued at USD 1.41 billion in 2025 and is projected to grow from USD 1.52 billion in 2026 to USD 2.83 billion by 2034, registering a CAGR of 8.06% during the forecast period (2026–2034). North America dominated the lung cancer genomic testing market with a market share of 40.34% in 2025.
Lung cancer genomic testing involves analyzing tumor DNA and genetic mutations to identify biomarkers that guide targeted therapies and personalized treatment decisions. These tests detect alterations such as EGFR, ALK, ROS1, KRAS, and other actionable mutations, helping clinicians select effective therapies while improving diagnostic accuracy.
The lung cancer genomic testing market demand is driven by the rising prevalence of lung cancer, growing adoption of precision medicine, expanding targeted therapies, and advances in next-generation sequencing, contributing to lung cancer genomic testing market growth globally.
Download a Free Sample To learn more about this report,
The lung cancer genomic testing market is sensitive to disruptions due to its dependence on advanced sequencing instruments, specialized reagents, laboratory consumables, and globally sourced diagnostic components. Supply chain disruptions have affected the timely availability of testing kits, sequencing platforms, and logistics for sample transportation, resulting in delayed diagnostic workflows and reduced laboratory efficiency across multiple regions. The market is experiencing a capacity-constrained recovery, supported by supplier diversification, localized manufacturing, strategic inventory management, and investments in resilient diagnostic supply networks.
The lung cancer genomic testing market is witnessing a transition from single-gene assays to AI-enabled multi-omics platforms that integrate genomic, transcriptomic, and clinical data for comprehensive treatment selection. This shift is improving the identification of actionable biomarkers, supporting personalized therapies, and enhancing clinical decision-making. Healthcare providers are increasingly adopting these advanced analytical platforms to improve diagnostic confidence and patient outcomes. For example, Tempus AI combines artificial intelligence with molecular and clinical datasets to support precision oncology workflows.
The market is experiencing growing adoption of liquid biopsy technologies as healthcare providers increasingly prefer minimally invasive genomic testing for lung cancer diagnosis and treatment monitoring. This transition is enabling faster detection of actionable mutations, facilitating repeat testing, and improving access to precision medicine for patients who cannot undergo tissue biopsy. As a result, liquid biopsy is becoming an important complement to conventional tissue-based testing across oncology practices. For example, Guardant Health offers liquid biopsy genomic tests that identify clinically relevant mutations in patients with advanced lung cancer.
The lung cancer genomic testing market forecasts sustained investment activity due to increasing adoption of precision oncology, rising demand for liquid biopsy and companion diagnostics, and expanding integration of AI-driven genomic analysis into clinical workflows.
In 2025, Caris Life Sciences completed its Nasdaq initial public offering, raising approximately USD 423.5 million to accelerate the expansion of its precision oncology business. The capital is being utilized to strengthen commercialization of its comprehensive molecular profiling and genomic testing portfolio, expand laboratory and bioinformatics capabilities, advance companion diagnostic development, and support research across multiple cancer types.
Increasing Adoption of Precision Oncology and Advancements in Next-Generation Sequencing Drives Market
The growing adoption of precision oncology is driving demand for lung cancer genomic testing by enabling clinicians to identify actionable genetic mutations and match patients with targeted therapies. Healthcare systems are increasingly incorporating biomarker testing into standard treatment pathways to improve clinical outcomes and reduce ineffective treatments. The expanding availability of targeted drugs for mutations such as EGFR, ALK, ROS1, KRAS, and BRAF further increases the need for comprehensive genomic profiling before treatment initiation.
Continuous advancements in next generation sequencing technologies are increasing the speed, scalability, and analytical performance, thereby strengthening market demand. New sequencing platforms are enabling laboratories to process larger sample volumes with shorter turnaround times while maintaining high sequencing accuracy, making comprehensive genomic profiling more accessible. These innovations are helping healthcare providers improve workflow efficiency and support faster treatment decisions for patients with non-small cell lung cancer.
High Cost of Comprehensive Genomic Testing and Limited Access to Standardized Biomarker Testing Restrain Market Expansion
Comprehensive genomic testing requires advanced next-generation sequencing instruments, specialized bioinformatics platforms, and highly trained personnel, resulting in significant capital and operational costs. Smaller hospitals and diagnostic laboratories, particularly in developing regions, often face budget constraints that limit the adoption of advanced genomic testing services.
Differences in reimbursement policies and uneven access to standardized biomarker testing limit the routine implementation of lung cancer genomic testing across healthcare systems. Many healthcare providers face challenges in recovering the costs associated with comprehensive genomic profiling, while limited testing infrastructure delays access to precision oncology services.
Expansion of Comprehensive Genomic Profiling and Decentralization of Next-generation Sequencing Offer Growth Opportunities to Market Players
The increasing use of comprehensive genomic profiling in early-stage lung cancer creates significant growth opportunities for genomic testing companies, sequencing platform manufacturers, and diagnostic laboratories. Earlier molecular characterization enables clinicians to identify patients who may benefit from targeted therapies and clinical trials before disease progression. As treatment guidelines continue to expand biomarker testing across earlier stages of lung cancer, demand for advanced genomic assays is expected to grow.
The expansion of national oncology networks is creating significant opportunities for genomic testing laboratories, bioinformatics providers, and companion diagnostic developers. Governments and healthcare systems are increasingly integrating comprehensive genomic profiling into nationwide cancer care pathways, increasing testing volumes and improving access to precision medicine. This transition is expected to generate long-term demand for standardized genomic testing services, data interpretation platforms, and molecular diagnostics.
Complex Interpretation of Genomic Variants and Fragmented Companion Diagnostic Approvals Challenges Market Growth
A major challenge for the lung cancer genomic testing market is the interpretation of complex genomic variants and the continuous emergence of new clinically relevant biomarkers. Laboratories must frequently update bioinformatics pipelines, variant databases, and reporting standards to align with evolving scientific evidence and treatment guidelines. This increases reporting complexity, delays clinical decision making, and creates variability in test interpretation, limiting the scalability of precision oncology services.
The co-development of companion diagnostics and targeted therapies often results in different regulatory approvals, testing requirements, and biomarker eligibility criteria across regions. This creates complexity for clinical laboratories and healthcare providers in selecting the appropriate test for each therapy, slowing the adoption of standardized genomic testing workflows. For example, different targeted therapies for EGFR, ALK, and MET alterations may have therapy-specific companion diagnostic requirements, increasing operational complexity for oncology laboratories.
Request Customizationto receive a tailored report.
The reagents & consumables segment accounted for a share of 37.58% in 2025 due to recurring requirement for extraction kits, library preparation reagents, and sequencing consumables in every genomic test.
The services segment is expected to grow at a CAGR of around 8.73% during the forecast period due to rising outsourcing of genomic data interpretation and increasing demand for clinical bioinformatics support. Growing adoption of centralized testing services by hospitals also accelerates segment expansion.
In 2025, next generation sequencing accounted for a share of 40.31% in 2025, as it simultaneously identify multiple actionable biomarkers through a single workflow. High multiplexing efficiency and compatibility with comprehensive companion diagnostic panels further strengthen its adoption.
The fluorescence in situ hybridization segment is expected to grow at a CAGR of 9.14% during the forecast period, driven by high analytical specificity for detecting chromosomal rearrangements and gene fusions. Continued clinical use for confirming ALK and ROS1 alterations also supports segment growth.
The tissue biopsy segment is expected to grow at a CAGR of 8.67% during the forecast period. This is due to superior DNA quality and preserved tumor architecture for comprehensive molecular profiling. It also enables simultaneous histopathological evaluation alongside genomic analysis.
The liquid biopsy segment is expected to grow at a CAGR of 9.20% during the forecast period, driven by increasing adoption for longitudinal disease monitoring and treatment resistance assessment. Its ability to facilitate repeated testing with minimal patient discomfort further supports growth.
The multi gene panel is estimated to grow at a CAGR of 8.81% during the forecast period, as expanding targeted therapies require simultaneous evaluation of multiple genomic alterations. These panels also maximize diagnostic information from limited tissue specimens.
The single gene panel segment is projected to grow at a CAGR of 9.25% during the forecast timeframe, owing to rapid detection of established actionable biomarkers for immediate treatment selection. Lower analytical complexity also supports wider implementation in routine diagnostic laboratories
Hospitals accounted for a share of 41.06% in 2025 due to integrated oncology care pathways that combine diagnosis, genomic testing, and targeted treatment within one facility. Multidisciplinary tumor boards also encourage routine molecular testing for treatment planning.
The diagnostic laboratories segment is projected to grow at a CAGR of 9.18% during the forecast period, due to expanding high throughput sequencing infrastructure and increasing laboratory automation. Their capability to process large testing volumes from multiple healthcare providers further drives segment growth.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Precision Oncology Adoption and Advanced Genomic Testing Infrastructure
The North America lung cancer genomic testing market accounted for the largest regional share of 40.34% in 2025, driven by adoption of precision oncology, routine biomarker testing for non-small cell lung cancer, and strong availability of next generation sequencing infrastructure. The region also benefits from favorable clinical guideline adoption, advanced molecular diagnostic laboratories, and extensive collaboration between pharmaceutical and diagnostics companies. According to the American Cancer Society, lung cancer remains one of the most frequently diagnosed cancers in the US, supporting sustained demand for comprehensive genomic profiling and companion diagnostics.
The US lung cancer genomic testing market was valued at USD 495.99 million in 2025, driven by implementation of comprehensive genomic profiling in clinical oncology and increasing use of companion diagnostics for targeted therapies. Healthcare providers are increasingly integrating NGS-based testing into standard care pathways to identify actionable biomarkers before treatment initiation. The country's extensive network of accredited molecular laboratories, academic cancer centers, and strong precision medicine ecosystem continues to support widespread adoption of advanced genomic testing technologies.
The lung cancer genomic testing market in Canada was valued at USD 72.81 million in 2025, driven by expanding provincial precision medicine initiatives and increasing access to molecular diagnostics through publicly funded healthcare systems. Cancer centers are strengthening genomic testing capabilities to improve targeted therapy selection and personalized treatment planning for lung cancer patients. Growing investments in genomic medicine programs, collaborative cancer research, and centralized molecular diagnostic laboratories continue to create favorable conditions for adoption across the country.
Asia Pacific: Fastest Growth Driven by Expanding National Genomics Programs and Increasing Access to Precision Oncology
The Asia Pacific lung cancer genomic testing market is expected to grow at a CAGR of 10.20% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding national genomics initiatives, increasing availability of molecular pathology services, and rising integration of precision oncology into public healthcare systems. Governments across the region are investing in genomic medicine infrastructure, cancer genomics research, and localized sequencing capabilities to improve personalized cancer care. According to the International Agency for Research on Cancer, Asia accounts for the largest share of global lung cancer incidence, creating substantial demand for genomic testing services.
The China lung cancer genomic testing market was valued at USD 82.01 million in 2025, supported by expansion of National Cancer Regional Medical Centers and increasing clinical adoption of domestically developed NGS based companion diagnostics approved by the National Medical Products Administration. The country's Healthy China 2030 initiative and large-scale genomic databases are accelerating precision oncology implementation, while the presence of leading domestic genomic companies is improving access to molecular testing across tertiary cancer hospitals.
The India lung cancer genomic testing market was valued at USD 41.95 million in 2025, fueled by the expansion of molecular pathology laboratories and the increasing availability of affordable indigenous genomic testing services. Growing collaborations between tertiary cancer hospitals and genomic diagnostic providers are improving access to biomarker testing beyond metropolitan cities. The country's expanding network of precision oncology centers is accelerating the adoption of comprehensive genomic profiling.
The Japan lung cancer genomic testing market was valued at USD 48.40 million in 2025, supported by Japan’s universal reimbursement for comprehensive genomic profiling under the national health insurance system and the expanding use of Cancer Genomic Medicine hospitals designated by the Ministry of Health, Labour and Welfare. Japan's strong focus on identifying EGFR mutations, which occur at a relatively higher frequency among East Asian NSCLC patients, continues to drive routine genomic testing and precision treatment selection across oncology centers.
Unlock Regional Insightsto access country-level data, & regional trends.
The lung cancer genomic testing market competitive landscape is moderately fragmented, with the presence of global molecular diagnostics manufacturers, specialized genomic testing laboratories, and emerging precision oncology firms. Established players primarily compete based on testing portfolios, technological capabilities, regulatory approvals, strategic collaborations with pharmaceutical companies, and strong clinical evidence supporting their assays. Emerging companies focus on developing innovative biomarker discovery platforms, decentralized testing solutions, and advanced bioinformatics capabilities to differentiate their offerings. The market ecosystem is further driven by product innovation, expansion of companion diagnostics, and integration of multiomics technologies.
June 2026: Guardant Health received US FDA approval for Guardant360 CDx as the companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib) to identify patients with HER2-mutant advanced non-small cell lung cancer (NSCLC) eligible for targeted therapy.
May 2026: Tempus AI received US FDA approval for the tumor-only indication of its xT CDx comprehensive genomic profiling assay, making it the first laboratory with FDA-approved companion diagnostic indications for both tumor-only and tumor-normal comprehensive genomic profiling.
March 2026: Illumina and Labcorp expanded their strategic collaboration to improve access to next-generation sequencing (NGS)-based precision oncology testing, including distributed biomarker testing, evidence generation for payer coverage, and development of new genomic assays.
September 2025: Illumina announced new partnerships with multiple global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology Comprehensive genomic profiling test, with an initial focus on KRAS biomarkers for precision oncology.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com